Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .
Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction.
The original Norwegian Multicenter Study on  Timolol after Myocardial Infa rct ion was a double-blind , r and omized study comparing the effect of timolol with that of placebo for up to 33 months after acute myocardial infa rct ion . The initial results showed that the cumulated mortality rate was 39.4 per cent lower among 945 patients r and omly assigned to  timolol  treatment than among 939 patients r and omly assigned to  placebo  ( P = 0.0003 ) . After the end of the double-blind period the majority of participating patients in the timolol group continued to receive beta-adrenergic blockade , whereas the majority of  placebo-treated patients continued without such blockade . During an extended follow-up of participating patients up to 72 months after r and omization , the mortality curves of the two groups continued to rise in parallel . Cumulated mortality rates were 32.3 per cent in the placebo group and 26.4 per cent in the timolol group ( P = 0.0028 ) . We conclude that the previously observed early beneficial effect of beta-adrenergic blocking therapy is maintained for at least six years after infa rct ion
Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .